Loading...
Market
Will Syndax receive additional FDA approvals for Revuforj® by end of 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
FDA announcements and Syndax Pharmaceuticals press releases
Story
Syndax Secures FDA Approval for Revuforj®, First Menin Inhibitor for Relapsed Acute Leukemia, Shares Rise 4.3%
Nov 18, 2024, 06:16 PM
Syndax Pharmaceuticals has received U.S. Food and Drug Administration (FDA) approval for its leukemia treatment, Revuforj® (revumenib). This drug is notable for being the first and only menin inhibitor approved for treating both adult and pediatric patients with relapsed or refractory acute leukemia featuring a KMT2A translocation. The approval marks a significant achievement for Syndax, especially following previous disappointments in other acute leukemia indications. Following the announcement, shares of Syndax ($SNDX) rose by 4.3% in pre-market trading.
View original story
Similar markets
Revuforj holds the largest market share • 25%
Revuforj holds the second largest market share • 25%
Revuforj holds the third largest market share • 25%
Revuforj holds less than third place in market share • 25%
Accelerated Approval • 25%
Full Approval • 25%
Conditional Approval • 25%
No Approval • 25%
FDA only • 25%
EMA only • 25%
Both FDA and EMA • 25%
Neither • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
